Atherosclerosis

1. BOREN J, Oorni K, Catapano AL
   The link between diabetes and cardiovascular disease.
   Atherosclerosis. 2024 May 29:117607. doi: 10.1016/j.atherosclerosis.2024.117607.
   

   >> Share

   
   

   
   BMC Ophthalmol

2. MOSHFEGHI AA, Khurana RN, Moini H, Sherman S, et al
   Impact of anti-VEGF treatment on development of proliferative diabetic retinopathy in routine clinical practice.
   BMC Ophthalmol. 2024;24:229.
   

   >> Share

   
   

   
   BMJ

3. 
   New advances in type 1 diabetes.
   BMJ. 2024;385:q1224.
   

   >> Share

   
   

   
   Diabet Med

4. KOURPAS E, Makrilakis K, Dafoulas G, Iotova V, et al
   Factors affecting continuous participation in follow-up evaluations during a lifestyle intervention programme for type 2 diabetes prevention: The Feel4Diabetes-study.
   Diabet Med. 2024 Jun 5:e15368. doi: 10.1111/dme.15368.
   

   >> Share

   
   
5. MURPHY JC, Cooke D, Griffiths D, Setty E, et al
   Asking women with diabetes about sexual problems: An exploratory study of NHS professionals' attitudes and practice: A survey of healthcare professionals regarding communication and silences about sexual problems during the routine care of women with
   Diabet Med. 2024 Jun 4:e15370. doi: 10.1111/dme.15370.
   

   >> Share

   
   
6. ROBERTSON E, Sutcliffe J, Connor R, Heller SR, et al
   The type 1 diabetes grand challenge: The potential for transformative impact from the largest ever investment, pound50 million and collaborative thinking across the UK.
   Diabet Med. 2024 Jun 4:e15376. doi: 10.1111/dme.15376.
   

   >> Share

   
   
7. LAWTON J, Rankin D, Scott E, Lorencatto F, et al
   From educator to facilitator: Healthcare professionals' experiences of, and views about, delivering a type 1 diabetes structured education programme (DAFNEplus ) informed by behavioural science.
   Diabet Med. 2024 Jun 4:e15375. doi: 10.1111/dme.15375.
   

   >> Share

   
   
8. 
   Correction to 'Producing a preference-based quality of LIFE measure to quantify the impact of HYPOGLYCAEMIA on people living with diabetes: A mixed-methods research protocol'Carlton J, Powell P, Rowen D, Broadley M, Pouwer F, Speight J, Heller S, Gall
   Diabet Med. 2024 Jun 5:e15351. doi: 10.1111/dme.15351.
   

   >> Share

   
   
9. MCMULLEN B, Duncanson K, Collins C, MacDonald-Wicks L, et al
   A systematic review of the mechanisms influencing engagement in diabetes prevention programmes for people with pre-diabetes.
   Diabet Med. 2024 Jun 3:e15323. doi: 10.1111/dme.15323.
   

   >> Share

   
   

   
   Diabetes

10. LI X, Yuan D, Zhang P, Luo C, et al
    A neural-mast cell axis regulates skin microcirculation in diabetes.
    Diabetes. 2024 Jun 4:db230862. doi: 10.2337/db23-0862.
    

    >> Share

    
    

    
    Diabetes Care

11. DRUCKER DJ
    Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.
    Diabetes Care. 2024 Jun 6:dci240003. doi: 10.2337/dci24-0003.
    

    >> Share

    
    
12. KAZE AD, Santhanam P, Ahima RS, Bertoni AG, et al
    Association Between Microvascular Disease and Cardiorespiratory Fitness Among Adults With Type 2 Diabetes.
    Diabetes Care. 2024 Jun 5:dc240294. doi: 10.2337/dc24-0294.
    

    >> Share

    
    
13. LEE H, Choi J, Kim JI, Watanabe RM, et al
    Higher Genetic Risk for Type 2 Diabetes Is Associated With a Faster Decline of beta-Cell Function in an East Asian Population.
    Diabetes Care. 2024 Jun 3:dc240058. doi: 10.2337/dc24-0058.
    

    >> Share

    
    

    
    Diabetes Obes Metab

14. GOLDENBERG RM
    A comment on 'Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials'.
    Diabetes Obes Metab. 2024;26:2997-2999.
    

    >> Share

    
    
15. BUTTICE L, Ghani M, Suthakar J, Gnanalingham S, et al
    The effect of sodium-glucose cotransporter-2 inhibitors on inflammatory biomarkers: A meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2024;26:2706-2721.
    

    >> Share

    
    
16. ZHANG J, Xu S, Liu X, Zhang J, et al
    Time trends and regional variation in utilization of antidiabetic medicines in China, 2015-2022.
    Diabetes Obes Metab. 2024;26:2752-2760.
    

    >> Share

    
    
17. WHITE T, Selvarajah V, Wolfhagen-Sand F, Svangard N, et al
    Prediction of cardiovascular risk factors from retinal fundus photographs: Validation of a deep learning algorithm in a prospective non-interventional study in Kenya.
    Diabetes Obes Metab. 2024;26:2722-2731.
    

    >> Share

    
    
18. ALMEIDA OP, Fong Z, Hill Almeida LM, Sanfilippo FM, et al
    Cross-sectional, case-control and longitudinal associations between exposure to glucagon-like peptide-1 receptor agonists and the dispensing of antidepressants.
    Diabetes Obes Metab. 2024;26:2925-2932.
    

    >> Share

    
    
19. ODUTAYO A, Cosentino F, Pratley RE, Dagogo-Jack S, et al
    Hypoglycaemia and kidney events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial.
    Diabetes Obes Metab. 2024 Jun 5. doi: 10.1111/dom.15687.
    

    >> Share

    
    
20. SUN CJ, Nguyen E, Prentki M, Rabasa-Lhoret R, et al
    The daunting task of recruiting insulin-treated patients living with type 2 diabetes mellitus for intensive lifestyle interventions.
    Diabetes Obes Metab. 2024 Jun 5. doi: 10.1111/dom.15688.
    

    >> Share

    
    
21. YOSHIDA Y, Zu Y, Fan B, Li S, et al
    Cumulative effect of metabolic risk factors on left ventricular geometry in those with versus without early-onset type 2 diabetes or prediabetes: The Coronary Artery Risk Development in Young Adults (CARDIA) study.
    Diabetes Obes Metab. 2024 Jun 4. doi: 10.1111/dom.15681.
    

    >> Share

    
    
22. MARQUES P, Mavrakanas TA, Guida J, Gedeon T, et al
    Utilizing synchronous care to improve cardiovascular and renal health among patients with type 2 diabetes: Proof-of-concept results from the DECIDE-CV clinical programme.
    Diabetes Obes Metab. 2024 Jun 3. doi: 10.1111/dom.15691.
    

    >> Share

    
    
23. LONG J, Fang Q, Shi Z, Miao Z, et al
    Integrated biomarker profiling for predicting the response of type 2 diabetes to metformin.
    Diabetes Obes Metab. 2024 Jun 3. doi: 10.1111/dom.15689.
    

    >> Share

    
    
24. GONZALEZ-VIDAL T, Rivas-Otero D, Ramos-Ruiz G, Agueria-Cabal P, et al
    Impact of the basal/bolus ratio on continuous glucose monitoring parameters in patients with type 1 diabetes.
    Diabetes Obes Metab. 2024 Jun 3. doi: 10.1111/dom.15690.
    

    >> Share

    
    
25. HE Y, Kunutsor SK, Kingsnorth AP, Gillies C, et al
    Differential associations of risk factors with severe and non-severe hypoglycaemia: the Hypoglycaemia Assessment Tool prospective observational study in people with insulin-treated type 1 diabetes and type 2 diabetes.
    Diabetes Obes Metab. 2024 Jun 3. doi: 10.1111/dom.15677.
    

    >> Share

    
    
26. CHANG ML, Tai J, Cheng JS, Chen WT, et al
    Factors associated with treatment responses to pioglitazone in patients with steatotic liver disease: A 3-year prospective cohort study.
    Diabetes Obes Metab. 2024;26:2969-2978.
    

    >> Share

    
    

    
    Diabetologia

27. HTOO PT, Tesfaye H, Schneeweiss S, Wexler DJ, et al
    Effectiveness and safety of empagliflozin: final results from the EMPRISE study.
    Diabetologia. 2024;67:1328-1342.
    

    >> Share

    
    
28. BRAKENRIDGE CJ, Koster A, de Galan BE, Carver A, et al
    Associations of 24 h time-use compositions of sitting, standing, physical activity and sleeping with optimal cardiometabolic risk and glycaemic control: The Maastricht Study.
    Diabetologia. 2024;67:1356-1367.
    

    >> Share

    
    
29. GYLFE E, Tengholm A
    Bo Hellman, 19 June 1930-4 December 2023.
    Diabetologia. 2024;67:1165-1167.
    

    >> Share

    
    
30. 
    Up Front.
    Diabetologia. 2024;67:1163-1164.
    

    >> Share

    
    
31. VATANEN T, de Beaufort C, Marcovecchio ML, Overbergh L, et al
    Gut microbiome shifts in people with type 1 diabetes are associated with glycaemic control: an INNODIA study.
    Diabetologia. 2024 Jun 4. doi: 10.1007/s00125-024-06192.
    

    >> Share

    
    
32. GUDEMANN LM, Young KG, Thomas NJM, Hopkins R, et al
    Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approach.
    Diabetologia. 2024 Jun 5. doi: 10.1007/s00125-024-06190.
    

    >> Share

    
    

    
    Invest Ophthalmol Vis Sci

33. STINO H, Huber KL, Kunze L, Steiner I, et al
    Intereye Microvascular Differences in Patients With Same-Stage Diabetic Retinopathy Revealed by OCTA.
    Invest Ophthalmol Vis Sci. 2024;65:11.
    

    >> Share

    
    
34. JIANG K, Zhang F, Chen Y, Li X, et al
    Fosfenopril Attenuates Inflammatory Response in Diabetic Dry Eye Models by Inhibiting the TLR4/NF-kappaB/NLRP3 Signaling Pathway.
    Invest Ophthalmol Vis Sci. 2024;65:2.
    

    >> Share

    
    

    
    J Diabetes Complications

35. HALL RM, Marshall HJ, Parry-Strong A, Corley B, et al
    A randomised controlled trial of additional bolus insulin using an insulin-to-protein ratio compared with insulin-to-carbohdrate ratio alone in people with type 1 diabetes following a carbohydrate-restricted diet.
    J Diabetes Complications. 2024;38:108778.
    

    >> Share

    
    
36. SUZUKI T, Sato T, Tanaka M, Endo K, et al
    Tirzepatide ameliorates eating behaviors regardless of prior exposure to glucagon-like peptide receptor agonists in Japanese patients with type 2 diabetes mellitus.
    J Diabetes Complications. 2024;38:108779.
    

    >> Share

    
    

    
    JAMA

37. FUJIEDA T
    Medical Management vs Bariatric Surgery in Type 2 Diabetes.
    JAMA. 2024 Jun 3. doi: 10.1001/jama.2024.8849.
    

    >> Share

    
    
38. COURCOULAS AP, Patti ME, Kirwan JP
    Medical Management vs Bariatric Surgery in Type 2 Diabetes-Reply.
    JAMA. 2024 Jun 3. doi: 10.1001/jama.2024.8852.
    

    >> Share

    
    

    
    Nature

39. FAIRBANK R
    Ozempic keeps wowing: trial data show benefits for kidney disease.
    Nature. 2024;630:16-17.
    

    >> Share

    
    

    
    Ophthalmol Retina

40. KUO BL, Tabano D, Garmo V, Kim E, et al
    Long-term Treatment Patterns for Diabetic Macular Edema: Up to 6-Year Follow-Up in the IRIS(R) Registry.
    Ophthalmol Retina. 2024 Jun 1:S2468-6530(24)00266.
    

    >> Share

    
    

    
    PLoS Med

41. ALI MK, Singh K, Kondal D, Devarajan R, et al
    Effect of a multicomponent quality improvement strategy on sustained achievement of diabetes care goals and macrovascular and microvascular complications in South Asia at 6.5 years follow-up: Post hoc analyses of the CARRS randomized clinical trial.
    PLoS Med. 2024;21:e1004335.
    

    >> Share

    
    

    
    PLoS One

42. THOMSON AM, Rioux BV, Hrubeniuk TJ, Bouchard DR, et al
    Does type 2 diabetes duration influence the effectiveness of an aerobic exercise intervention: Results from the INTENSITY study.
    PLoS One. 2024;19:e0304341.
    

    >> Share

    
    
43. EKELUND C, Dereke J, Nilsson C, Landin-Olsson M, et al
    Are soluble E-selectin, ICAM-1, and VCAM-1 potential predictors for the development of diabetic retinopathy in young adults, 15-34 years of age? A Swedish prospective cohort study.
    PLoS One. 2024;19:e0304173.
    

    >> Share

    
    
44. GONZALEZ-RODRIGUEZ JL, Franco C, Pinzon-Espitia O, Caballer V, et al
    Prediction of pharmaceutical and non-pharmaceutical expenditures associated with Diabetes Mellitus type II based on clinical risk.
    PLoS One. 2024;19:e0301860.
    

    >> Share

    
    
45. KIM W, Park SK, Kim YL
    Fetal abdominal obesity in women with one value abnormality on diagnostic test for gestational diabetes mellitus.
    PLoS One. 2024;19:e0304875.
    

    >> Share

    
    
46. LORD J, Odoi A
    Investigation of geographic disparities of diabetes-related hospitalizations in Florida using flexible spatial scan statistics: An ecological study.
    PLoS One. 2024;19:e0298182.
    

    >> Share

    
    
47. YOVERA-ALDANA M, Sifuentes-Hermenegildo P, Cervera-Ocana MS, Mezones-Holguin E, et al
    Association of multidrug-resistant bacteria and clinical outcomes in patients with infected diabetic foot in a Peruvian hospital: A retrospective cohort analysis.
    PLoS One. 2024;19:e0299416.
    

    >> Share

    
    
48. RIVARA AC, Russell EM, Carlson JC, Pomer A, et al
    Associations between fasting glucose rate-of-change and the missense variant, rs373863828, in an adult Samoan cohort.
    PLoS One. 2024;19:e0302643.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share